Literature DB >> 557071

Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex.

L O Andersson, L Engman, E Henningsson.   

Abstract

A two-dimensional immunoelectrophoretic method has been used to obtain information on the binding of heparin to purified antithrombin III and the antithrombin III--thrombin complex. The difference in mobility of the components in a gel containing heparin enables distinction between free and complexed forms of antithrombin III. The results obtained with purified preparations show that heparin is bound more strongly to antithrombin III than to the antithrombin III--thrombin complex. In plasma heparin is bound to several components, only a fraction being bound to antithrombin III. Several components containing antithrombin III are detectable in serum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 557071     DOI: 10.1016/0022-1759(77)90138-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  In vivo behaviour of some antithrombin III-protease complexes.

Authors:  L S Lam; E Regoeczi; M W Hatton
Journal:  Br J Exp Pathol       Date:  1979-04

2.  Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Authors:  J E Sambrano; L J Jacobson; E B Reeve; M J Manco-Johnson; W E Hathaway
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

Review 3.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

4.  Antithrombin III metabolism in patients with liver disease.

Authors:  E Knot; J W Ten Cate; H R Drijfhout; L H Kahlé; G N Tytgat
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

Review 5.  Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis.

Authors:  Christian J Wiedermann
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.